Repare Therapeutics Management
Management criteria checks 2/4
Repare Therapeutics' CEO is Lloyd Segal, appointed in Sep 2016, has a tenure of 8.08 years. total yearly compensation is $4.99M, comprised of 12.3% salary and 87.7% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $409.00K. The average tenure of the management team and the board of directors is 5.4 years and 4.9 years respectively.
Key information
Lloyd Segal
Chief executive officer
US$5.0m
Total compensation
| CEO salary percentage | 12.3% |
| CEO tenure | 8.1yrs |
| CEO ownership | 0.3% |
| Management average tenure | 5.4yrs |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib Data
Aug 30Will Repare Therapeutics (NASDAQ:RPTX) Spend Its Cash Wisely?
Jul 12
Repare Therapeutics Inc.'s (NASDAQ:RPTX) 34% Dip In Price Shows Sentiment Is Matching Revenues
May 01Benign Growth For Repare Therapeutics Inc. (NASDAQ:RPTX) Underpins Stock's 30% Plummet
Mar 12We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully
Feb 15Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Fly 30% But Investors Aren't Buying For Growth
Dec 20Here's Why We're Not At All Concerned With Repare Therapeutics' (NASDAQ:RPTX) Cash Burn Situation
Oct 24New Forecasts: Here's What Analysts Think The Future Holds For Repare Therapeutics Inc. (NASDAQ:RPTX)
Aug 14Analysts Are Betting On Repare Therapeutics Inc. (NASDAQ:RPTX) With A Big Upgrade This Week
May 14Analysts Are Upgrading Repare Therapeutics Inc. (NASDAQ:RPTX) After Its Latest Results
May 12Repare Therapeutics Inc. (NASDAQ:RPTX) Looks Inexpensive But Perhaps Not Attractive Enough
May 08Growth Investors: Industry Analysts Just Upgraded Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts By 31%
Mar 03Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Oct 27Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma Partners
Sep 07Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Aug 04Repare Therapeutics: Interesting Gene Editing Company, But Miles To Go
Jun 27Companies Like Repare Therapeutics (NASDAQ:RPTX) Are In A Position To Invest In Growth
Jun 24Repare Therapeutics (NASDAQ:RPTX) Is In A Good Position To Deliver On Growth Plans
Mar 02We're Not Worried About Repare Therapeutics' (NASDAQ:RPTX) Cash Burn
Oct 14We Think Repare Therapeutics (NASDAQ:RPTX) Can Easily Afford To Drive Business Growth
Apr 16Have Repare Therapeutics Inc. (NASDAQ:RPTX) Insiders Been Selling Their Stock?
Mar 12Are Institutions Heavily Invested In Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares?
Feb 08
Repare Therapeutics: CRISPR-Enabled Technology Might Unlock New Therapies
Dec 28Trade Alert: The Executive VP & Head of Business & Corporate Development Of Repare Therapeutics Inc. (NASDAQ:RPTX), Kim Seth, Has Sold Some Shares Recently
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$69m |
| Mar 31 2024 | n/a | n/a | -US$46m |
| Dec 31 2023 | US$5m | US$615k | -US$94m |
| Sep 30 2023 | n/a | n/a | -US$97m |
| Jun 30 2023 | n/a | n/a | -US$3m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$4m | US$592k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$26m |
| Jun 30 2022 | n/a | n/a | -US$132m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$4m | US$572k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$94m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$62m |
| Dec 31 2020 | US$5m | US$505k | -US$53m |
| Sep 30 2020 | n/a | n/a | -US$46m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$430k | -US$27m |
Compensation vs Market: Lloyd's total compensation ($USD4.99M) is above average for companies of similar size in the US market ($USD677.23K).
Compensation vs Earnings: Lloyd's compensation has increased whilst the company is unprofitable.
CEO
Lloyd Segal (60 yo)
8.1yrs
Tenure
US$4,991,804
Compensation
Mr. Lloyd Mitchell Segal serves as Director at HotKnot Therapeutics, Inc. Mr. Segal has been the Chief Executive Officer, President and Director of Repare Therapeutics Inc. since September 2016. Mr. Segal...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.1yrs | US$4.99m | 0.28% $ 409.0k | |
| Executive VP & CFO | 5yrs | US$1.93m | 0.034% $ 50.0k | |
| Executive VP & Chief Medical Officer | 5.4yrs | US$2.09m | 0.47% $ 693.2k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Executive VP & Chief Scientific Officer | 5.4yrs | US$1.83m | 0.098% $ 144.1k | |
| Executive Vice President of Human Resource | 1.4yrs | no data | 0.0037% $ 5.4k | |
| Executive Vice President of Discovery | 8.3yrs | no data | 0.055% $ 81.3k | |
| Executive VP | 2.8yrs | no data | 0.0092% $ 13.6k |
5.4yrs
Average Tenure
53yo
Average Age
Experienced Management: RPTX's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.1yrs | US$4.99m | 0.28% $ 409.0k | |
| Independent Director | 4.3yrs | US$274.74k | 0.0094% $ 13.9k | |
| Independent Director | 5.1yrs | US$265.41k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$664.86k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$268.78k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 4.9yrs | US$265.31k | 0% $ 0 | |
| Independent Chairman | 3.1yrs | US$291.49k | 0.018% $ 26.0k | |
| Independent Director | 5.6yrs | US$272.99k | 0.019% $ 27.8k |
4.9yrs
Average Tenure
59yo
Average Age
Experienced Board: RPTX's board of directors are considered experienced (4.9 years average tenure).